NEW
Stock Screener with Intrinsic Value
Novo Nordisk A/S (NVO)
Last Price$86.30.8%
Market Cap$384.7B
DCF value
$83.3
Overvalued (DCF value)
(3.5%)
Discount Rate
7.9%
Long-Term Growth Rate
3.0%
Stock quality
7/10
Good
NVO DCF Model
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
NVO DCF Value
Crunching data... Almost there!
NVO DCF Financials
Crunching data... Almost there!
NVO DCF sensitivity
Crunching data... Almost there!
Explore more intrinsic value tools hub for NVO
Margin of safety
Peter Lynch charts
Ben Graham Fair Value
Earnings Power Value
Relative Value
Earnings growth model
Discount rate
Peter Lynch Fair Value
Intrinsic Value
Reverse DCF
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Novo Nordisk A/S DCF (discounted cash flow) valuation?
As of Jan 10, 2025, Novo Nordisk A/S's Discounted Cash Flow (DCF) valuation estimates its share price at $83.3. This suggests it may be overvalued by (3.5%) compared to its current price of around $86.3, using a WACC of 7.9% and growth rates of 3.0%.
What is Novo Nordisk A/S WACC?
As of Jan 10, 2025, Novo Nordisk A/S's Weighted Average Cost of Capital (WACC) is approximately 7.9%.
What is Novo Nordisk A/S Enterprise Value?
As of Jan 10, 2025, Novo Nordisk A/S's Enterprise Value (EV) is approximately DKK 2,708.0B. This value reflects the company's total market capitalization plus debt, minus cash and cash equivalents, providing a comprehensive measure of its overall value in the market.